|
1
|
Lee N and Kim D: Cancer Metabolism:
Fueling more than just growth. Mol Cells. 39:847–854. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Doherty JR and Cleveland JL: Targeting
lactate metabolism for cancer therapeutics. J Clin Invest.
123:3685–3692. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rho M, Kim J, Jee CD, Lee YM, Lee HE, Kim
MA, Lee HS and Kim WH: Expression of type 2 hexokinase and
mitochondria-related genes in gastric carcinoma tissues and cell
lines. Anticancer Res. 27A:1–258. 2007.
|
|
5
|
Palmieri D, Fitzgerald D, Shreeve SM, Hua
E, Bronder JL, Weil RJ, Davis S, Stark AM, Merino MJ, Kurek R, et
al: Analyses of resected human brain metastases of breast cancer
reveal the association between up-regulation of hexokinase 2 and
poor prognosis. Mol Cancer Res. 7:1438–1445. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu Y, Wu K, Shi L, Xiang F, Tao K and
Wang G: Prognostic significance of the metabolic marker
hexokinase-2 in various solid tumors: A meta-analysis. PLoS One.
11:e01662302016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang ZF, Feng XS, Chen H, Duan ZJ, Wang
LX, Yang D, Liu PX, Zhang QP, Jin YL, Sun ZG, et al: Prognostic
significance of synergistic hexokinase-2 and beta2-adrenergic
receptor expression in human hepatocelluar carcinoma after curative
resection. BMC Gastroenterol. 16:572016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kwee SA, Hernandez B, Chan O and Wong L:
Choline kinase alpha and hexokinase-2 protein expression in
hepatocellular carcinoma: Association with survival. PLoS One.
7:e465912012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hamabe A, Yamamoto H, Konno M, Uemura M,
Nishimura J, Hata T, Takemasa I, Mizushima T, Nishida N, Kawamoto
K, et al: Combined evaluation of hexokinase 2 and phosphorylated
pyruvate dehydrogenase-E1α in invasive front lesions of colorectal
tumors predicts cancer metabolism and patient prognosis. Cancer
Sci. 105:1100–1108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu X, Deng Q, Li W, Xiao L, Luo X, Liu X,
Yang L, Peng S, Ding Z, Feng T, et al: Neoalbaconol induces cell
death through necroptosis by regulating RIPK-dependent autocrine
TNFα and ROS production. Oncotarget. 6:1995–2008. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu X, Li W, Deng Q, You S, Liu H, Peng S,
Liu X, Lu J, Luo X, Yang L, et al: Neoalbaconol inhibits
angiogenesis and tumor growth by suppressing EGFR-mediated VEGF
production. Mol Carcinog. 56:1414–1426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee KW, Bode AM and Dong Z: Molecular
targets of phytochemicals for cancer prevention. Nat Rev Cancer.
11:211–218. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen X, Liu Z, Meng R, Shi C and Guo N:
Antioxidative and anticancer properties of Licochalcone A from
licorice. J Ethnopharmacol. 198:331–337. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu J and Liu J: Licochalcone A attenuates
kipopolysaccharide-induced acute kidney injury by inhibiting NF-κB
activation. Inflammation. 39:569–574. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang L, Yang R, Yuan B, Liu Y and Liu C:
The antiviral and antimicrobial activities of licorice, a
widely-used Chinese herb. Acta Pharm Sin B. 5:310–315. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bortolotto LF, Barbosa FR, Silva G,
Bitencourt TA, Beleboni RO, Baek SJ, Marins M and Fachin AL:
Cytotoxicity of trans-chalcone and licochalcone A against breast
cancer cells is due to apoptosis induction and cell cycle arrest.
Biomed Pharmacother. 85:425–433. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tang ZH, Chen X, Wang ZY, Chai K, Wang YF,
Xu XH, Wang XW, Lu JH, Wang YT, Chen XP, et al: Induction of C/EBP
homologous protein-mediated apoptosis and autophagy by licochalcone
A in non-small cell lung cancer cells. Sci Rep. 6:262412016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Park MR, Kim SG, Cho IA, Oh D, Kang KR,
Lee SY, Moon SM, Cho SS, Yoon G, Kim CS, et al: Licochalcone-A
induces intrinsic and extrinsic apoptosis via ERK1/2 and p38
phosphorylation-mediated TRAIL expression in head and neck squamous
carcinoma FaDu cells. Food Chem Toxicol. 77:34–43. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tsai JP, Lee CH, Ying TH, Lin CL, Lin CL,
Hsueh JT and Hsieh YH: Licochalcone A induces autophagy through
PI3K/Akt/mTOR inactivation and autophagy suppression enhances
Licochalcone A-induced apoptosis of human cervical cancer cells.
Oncotarget. 6:28851–28866. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang HC, Tsai LL, Tsai JP, Hsieh SC, Yang
SF, Hsueh JT and Hsieh YH: Licochalcone A inhibits the migration
and invasion of human lung cancer cells via inactivation of the Akt
signaling pathway with downregulation of MMP-1/-3 expression.
Tumour Biol. 35:12139–12149. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim YH, Shin EK, Kim DH, Lee HH, Park JH
and Kim JK: Antiangiogenic effect of licochalcone A. Biochem
Pharmacol. 80:1152–1159. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kinghorn AD, DE Blanco EJ, Lucas DM,
Rakotondraibe HL, Orjala J, Soejarto DD, Oberlies NH, Pearce CJ,
Wani MC, Stockwell BR, et al: Discovery of anticancer agents of
diverse natural origin. Anticancer Res. 36:5623–5637. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hao W, Yuan X, Yu L, Gao C, Sun X, Wang D
and Zheng Q: Licochalcone A-induced human gastric cancer BGC-823
cells apoptosis by regulating ROS-mediated MAPKs and PI3K/AKT
signaling pathways. Sci Rep. 5:103362015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee JW, Lee SM, Lee MS and Shin HC: Role
of ¹8F-FDG PET/CT in the prediction of gastric cancer
recurrence after curative surgical resection. Eur J Nucl Med Mol
Imaging. 39:1425–1434. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Coupe NA, Karikios D, Chong S, Yap J, Ng
W, Merrett N and Lin M: Metabolic information on staging FDG-PET-CT
as a prognostic tool in the evaluation of 97 patients with gastric
cancer. Ann Nucl Med. 28:128–135. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Watanabe Y, Suefuji H, Hirose Y, Kaida H,
Suzuki G, Uozumi J, Ogo E, Miura M, Takasu K, Miyazaki K, et al:
18F-FDG uptake in primary gastric malignant lymphoma
correlates with glucose transporter 1 expression and histologic
malignant potential. Int J Hematol. 97:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Qiu MZ, Han B, Luo HY, Zhou ZW, Wang ZQ,
Wang FH, Li YH and Xu RH: Expressions of hypoxia-inducible
factor-1α and hexokinase-II in gastric adenocarcinoma: The impact
on prognosis and correlation to clinicopathologic features. Tumour
Biol. 32:159–166. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yin L, Wang X, Luo C, Liu H, Zhang L,
Zhang H and Zhang Y: The value of expression of M2-PK and VEGF in
patients with advanced gastric cancer. Cell Biochem Biophys.
67:1033–1039. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lim JY, Yoon SO, Seol SY, Hong SW, Kim JW,
Choi SH and Cho JY: Overexpression of the M2 isoform of pyruvate
kinase is an adverse prognostic factor for signet ring cell gastric
cancer. World J Gastroenterol. 18:4037–4043. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mathupala SP, Ko YH and Pedersen PL:
Hexokinase II: Cancer's double-edged sword acting as both
facilitator and gatekeeper of malignancy when bound to
mitochondria. Oncogene. 25:4777–4786. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen GQ, Tang CF, Shi XK, Lin CY, Fatima
S, Pan XH, Yang DJ, Zhang G, Lu AP, Lin SH, et al: Halofuginone
inhibits colorectal cancer growth through suppression of Akt/mTORC1
signaling and glucose metabolism. Oncotarget. 6:24148–24162.
2015.PubMed/NCBI
|
|
33
|
Li W, Ma X, Li N, Liu H, Dong Q, Zhang J,
Yang C, Liu Y, Liang Q, Zhang S, et al: Resveratrol inhibits
Hexokinases II mediated glycolysis in non-small cell lung cancer
via targeting Akt signaling pathway. Exp Cell Res. 349:320–327.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li W, Gao F, Ma X, Wang R, Dong X and Wang
W: Deguelin inhibits non-small cell lung cancer via down-regulating
Hexokinases II-mediated glycolysis. Oncotarget. 8:32586–32599.
2017.PubMed/NCBI
|
|
35
|
Zhuo B, Li Y, Li Z, Qin H, Sun Q, Zhang F,
Shen Y, Shi Y and Wang R: PI3K/Akt signaling mediated Hexokinase-2
expression inhibits cell apoptosis and promotes tumor growth in
pediatric osteosarcoma. Biochem Biophys Res Commun. 464:401–406.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhou Y, Lu N, Qiao C, Ni T, Li Z, Yu B,
Guo Q and Wei L: FV-429 induces apoptosis and inhibits glycolysis
by inhibiting Akt-mediated phosphorylation of hexokinase II in
MDA-MB-231 cells. Mol Carcinog. 55:1317–1328. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Suh DH, Kim MA, Kim H, Kim MK, Kim HS,
Chung HH, Kim YB and Song YS: Association of overexpression of
hexokinase II with chemoresistance in epithelial ovarian cancer.
Clin Exp Med. 14:345–353. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang L, Wang J, Xiong H, Wu F, Lan T,
Zhang Y, Guo X, Wang H, Saleem M, Jiang C, et al: Co-targeting
hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy
suppresses tumor growth of PTEN- and TP53-deficiency-driven
castration-resistant prostate cancer. EBioMedicine. 7:50–61. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang J, Duan Z, Nugent Z, Zou JX, Borowsky
AD, Zhang Y, Tepper CG, Li JJ, Fiehn O, Xu J, et al: Reprogramming
metabolism by histone methyltransferase NSD2 drives endocrine
resistance via coordinated activation of pentose phosphate pathway
enzymes. Cancer Lett. 378:69–79. 2016. View Article : Google Scholar : PubMed/NCBI
|
